Literature DB >> 12781551

Haemophilias A and B.

Paula H B Bolton-Maggs1, K John Pasi.   

Abstract

The haemophilias are inherited disorders in which one of the coagulation factors is deficient. Although deficiencies of factor VIII (haemophilia A) and factor IX (haemophilia B) are well recognised, von Willebrand's disease is much more common. Rare defects can occur in any of the coagulation factors. In the past, men with haemophilia were likely to die in their youth. With advances in diagnosis, and especially with development of safe and effective treatment, affected individuals can now look forward to a normal life expectancy. Complications of the disorder, particularly the development of antibodies that make treatment ineffective, and of treatment, such as transfusion-transmitted infections, have taken a severe toll on these patients. The future holds the realistic possibility of gene therapy. However, we must not forget that haemophilia is a worldwide disorder that requires significant economic resources not available for the majority.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781551     DOI: 10.1016/S0140-6736(03)13405-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  172 in total

1.  Antihemophilic factor [recombinant], formulated with sucrose.

Authors: 
Journal:  P T       Date:  2010-09

Review 2.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

Review 3.  Genetically engineered livestock for biomedical models.

Authors:  Christopher S Rogers
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

4.  Gut dysbiosis modulates the immune response to factor VIII in murine hemophilia A.

Authors:  Julie Tarrant; Matthew Cormier; Kate Nesbitt; Courtney Dwyer; Christine Hough; David Lillicrap
Journal:  Blood Adv       Date:  2020-06-23

Review 5.  Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders.

Authors:  M Asif A Siddiqui; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  A novel nonsense mutation in exon 2 of the factor IX gene resulting in severe haemophilia B.

Authors:  Marcello Niceta; Carmelo Fabiano; Pietro Sammarco; Fabio Gagliano; Giacomo Mancuso
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 7.  Endothelial progenitor cell-based therapy for hemophilia A.

Authors:  Hideto Matsui
Journal:  Int J Hematol       Date:  2012-02       Impact factor: 2.490

8.  Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.

Authors:  Vivek S Purohit; Sathyamangalam V Balasubramanian
Journal:  AAPS J       Date:  2006-05-26       Impact factor: 4.009

9.  Need for Prophylactic Treatment in Adult Haemophilia A Patients.

Authors:  Berthold Siegmund; Heinrich Richter; Hartmut Pollmann
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

10.  Protein S: a Multifunctional Anticoagulant.

Authors:  A'drianne Dorsey; Vijaya Satish Pilli; Howard Fried; Rinku Majumder
Journal:  Biomed Res Clin Pract       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.